Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?

Park, Jihye

doi:10.5217/ir.2021.00170

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with the treat-to-target concept now being emphasized, these immunosuppressive agents are being widely used at an early stage, and for long-term maintenance [5][6][7][8][9]. However, this treatment strategy carries an increased risk of opportunistic infections [10][11][12]. Accordingly, appropriate screening and vaccination programs are needed for patients with IBD [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Vaccination strategies for Korean patients with inflammatory bowel disease

Lee

Kim

2022

Korean J Intern Med

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) are vulnerable to vaccine-preventable infectious diseases. Immunosuppressive drugs, which are often used to manage IBD, may increase this vulnerability and attenuate vaccine efficacy. Thus, healthcare providers should understand infectious diseases and schedule vaccinations for them to reduce the infection-related burden of patients with IBD. All patients with IBD should be assessed in terms of immunity to vaccine-preventable diseases at the time of IBD diagnosis, and be vaccinated appropriately. Vaccination is becoming more important because of the unprecedented coronavirus disease 2019 (COVID-19) global health crisis. This review focuses on recent updates to vaccination strategies for Korean patients with IBD.

show abstract